GUTS
FRACTYL HEALTH, INC.
$0.8500
+17.40%
$134.9M
No data for this timeframe.
Vol
Market Cap$134.9M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders29 funds
Inst. Value$6.5M
Inst. Activity0 buys / 7 sells
Insider Activity4B / 0S
Insider Net $$107.8K
Reddit Sentiment40° Cool
SEC Reports9
Press Releases3
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001572616·Prev Close $0.7240
Recent Activity
Jun 12, 2026
SEC
Q3 2024 13F filings show mixed institutional activity in Fractyl Health (GUTS): four funds (Woodline Partners, Schwab, R
INST-CLUSTER — Impact 4/10
Jun 12, 2026
short_volume
Short Volume: GUTS — 60.1% short (1.1M / 1.9M)
Short: 1,118,861 | Exempt: 12,400 | TRF Vol: 1,860,980 | Short Ratio: 60.1% | Off-exchange volume (d
Jun 11, 2026
SEC
CEO Rajagopalan Harith and CFO Smith Weber Lara collectively purchased $32K worth of GUTS shares in open-market transact
CLUSTER — Impact 3/10
Jun 11, 2026
SEC
Three mega-passive institutional investors (Vanguard, Morgan Stanley, UBS) significantly increased their GUTS positions
INST-CLUSTER — Impact 3/10
Jun 10, 2026
Insider
Rajagopalan Harith bought 25,000 shares
Chief Executive Officer @ $0.7301 ($18.3K)
Jun 10, 2026
Insider
Elia Marc was granted 22,500 shares
Director
Jun 10, 2026
Insider
MEANWELL CLIVE was granted 22,500 shares
Director
Inst.
Woodline Partners LP — TRIM
2,241,679 shares ($1.0M)
Price Targets
$5.24
+516.5% upside
Strong Buy
Current $0.8500
Low $2.00
Median $6.20
High $8.00
5 analysts
$2.00
$8.00
Analyst Ratings
4Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 24, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 26, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Jan 30, 2026 | Morgan Stanley | DOWNGRADE | Overweight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.14 | $-0.15 — $-0.14 | 75% YoY | 5 |
| Next Q | $-0.14 | $-0.15 — $-0.14 | 80% YoY | 5 |
| Current FY | $-0.42 | $-0.58 — $-0.35 | 77% YoY | 5 |
| Next FY | $-0.54 | $-0.77 — $-0.36 | -30% YoY | 5 |
Latest Reports
MIXED
INST-CLUSTER
4/10
Q3 2024 13F filings show mixed institutional activity in Fractyl Health (GUTS): four funds (Woodline Partners, Schwab, R
Jun 12, 2026
NEUTRAL
CLUSTER
3/10
CEO Rajagopalan Harith and CFO Smith Weber Lara collectively purchased $32K worth of GUTS shares in open-market transact
Jun 11, 2026
BULLISH
Press
7/10
Fractyl Health reported positive one-year open-label data from its REVEAL-1 Cohort, showing that patients who underwent
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2.5M | — |
| Woodline Partners LP | $1.0M | TRIM |
| BlackRock, Inc. | $979.6K | DOUBLED |
| MARSHALL WACE, LLP | $371.6K | NEAR_EXIT |
| VANGUARD FIDUCIARY TRUST CO | $277.6K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Rajagopalan Harith | BUY | $18.3K |
| Jun 10, 2026 | Elia Marc | A | $0.00 |
| Jun 10, 2026 | MEANWELL CLIVE | A | $0.00 |
| Jun 10, 2026 | Conaway Samuel | A | $0.00 |
| Jun 10, 2026 | Sheffield Ian | BUY | $25.5K |
Reddit Sentiment
40°
Cool
Bearish
Neutral
Bullish
29 institutional holders with $6.5M total value (14,288,786 shares) as of 2026-Q1. Top holders: VANGUARD, Woodline, BlackRock,. Net selling activity: 7 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 5,533,006 | $2.5M | 38.8% | — |
| 2 | Woodline Partners LP | 2,241,679 | $1.0M | 15.7% | TRIM -59.3% |
| 3 | BlackRock, Inc. | 2,139,837 | $979.6K | 15.0% | DOUBLED +174.1% |
| 4 | MARSHALL WACE, LLP | 807,796 | $371.6K | 5.7% | NEAR_EXIT -86.4% |
| 5 | VANGUARD FIDUCIARY TRUST CO | 606,185 | $277.6K | 4.2% | — |
| 6 | MORGAN STANLEY | 495,901 | $227.0K | 3.5% | ADD +52.6% |
| 7 | TWO SIGMA INVESTMENTS, LP | 479,737 | $219.6K | 3.4% | — |
| 8 | STATE STREET CORP | 464,700 | $212.7K | 3.3% | DOUBLED +1156.6% |
| 9 | Brevan Howard Capital Management LP | 232,369 | $99.2K | 1.5% | TRIM -50.0% |
| 10 | PEAK6 LLC | 200,000 | $91.6K | 1.4% | — |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 176,087 | $80.6K | 1.2% | — |
| 12 | Cerity Partners LLC | 168,500 | $77.1K | 1.2% | DOUBLED +1105.2% |
| 13 | BANK OF AMERICA CORP /DE/ | 124,989 | $57.1K | 0.9% | NEAR_EXIT -89.5% |
| 14 | OMERS ADMINISTRATION Corp | 123,900 | $56.7K | 0.9% | TRIM -30.9% |
| 15 | BARCLAYS PLC | 116,048 | $53.1K | 0.8% | — |
| 16 | GOLDMAN SACHS GROUP INC | 68,433 | $31.3K | 0.5% | — |
| 17 | HighTower Advisors, LLC | 51,442 | $23.6K | 0.4% | — |
| 18 | CITADEL ADVISORS LLC | 48,196 | $22.1K | 0.3% | — |
| 19 | Vanguard Global Advisers, LLC | 41,311 | $18.9K | 0.3% | — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 35,200 | $16.1K | 0.2% | NEAR_EXIT -98.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Woodline Partners LP | TRIM | 5,506,771 | 2,241,679 | -59.3% | $1.0M | 2026-Q1 |
| MARSHALL WACE, LLP | NEAR_EXIT | 5,926,745 | 807,796 | -86.4% | $371.6K | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 464,738 | 232,369 | -50.0% | $99.2K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 1,192,236 | 124,989 | -89.5% | $57.1K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 179,300 | 123,900 | -30.9% | $56.7K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 1,863,051 | 35,200 | -98.1% | $16.1K | 2026-Q1 |
| Verition Fund Management LLC | TRIM | 54,910 | 19,971 | -63.6% | $9.1K | 2026-Q1 |
| VANGUARD GROUP INC | DOUBLED | 1,921,147 | 6,028,179 | +213.8% | $13.3M | 2025-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 1,769,776 | 5,926,745 | +234.9% | $13.0M | 2025-Q4 |
| Alyeska Investment Group, L.P. | TRIM | 5,648,371 | 3,809,523 | -32.6% | $8.4M | 2025-Q4 |
| BlackRock, Inc. | DOUBLED | 759,995 | 2,083,318 | +174.1% | $4.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 776,700 | 1,863,051 | +139.9% | $4.1M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | DOUBLED | 294,290 | 1,442,745 | +390.2% | $3.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 88,634 | 1,192,236 | +1245.1% | $2.6M | 2025-Q4 |
| MORGAN STANLEY | ADD | 430,231 | 656,482 | +52.6% | $1.4M | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 40,800 | 512,700 | +1156.6% | $1.1M | 2025-Q4 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 2,187,999 | 365,173 | -83.3% | $803.4K | 2025-Q4 |
| Cerity Partners LLC | DOUBLED | 13,566 | 163,500 | +1105.2% | $359.7K | 2025-Q4 |
| Centiva Capital, LP | TRIM | 49,340 | 17,419 | -64.7% | $38.3K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 4,696 | 149 | -96.8% | — | 2025-Q3 |
| Woodline Partners LP | DOUBLED | 597,841 | 5,506,534 | +821.1% | $8.8M | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 1,108,786 | 1,921,147 | +73.3% | $3.1M | 2025-Q3 |
| UBS Group AG | DOUBLED | 22,842 | 752,596 | +3194.8% | $1.2M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 156,890 | 430,231 | +174.2% | $684.1K | 2025-Q3 |
| Cerity Partners LLC | TRIM | 18,486 | 13,566 | -26.6% | $21.6K | 2025-Q3 |
10 unique insiders with 12 transactions. Net insider value: $107.8K ($107.8K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Rajagopalan Harith | Chief Executive Officer | BUY | 25,000 | $0.7301 | $18.3K |
| Jun 10, 2026 | Elia Marc | Director | AWARD | 22,500 | — | — |
| Jun 10, 2026 | MEANWELL CLIVE | Director | AWARD | 22,500 | — | — |
| Jun 10, 2026 | Conaway Samuel | Director | AWARD | 22,500 | — | — |
| Jun 10, 2026 | Sheffield Ian | Director | BUY | 35,000 | $0.7294 | $25.5K |
| Jun 10, 2026 | Sheffield Ian | Director | AWARD | 22,500 | — | — |
| Jun 10, 2026 | Barnes Kelly Ann | Director | AWARD | 22,500 | — | — |
| Jun 10, 2026 | Royan Ajay | Director | AWARD | 22,500 | — | — |
| Jun 10, 2026 | Thompson Christopher Charles | Director | AWARD | 22,500 | — | — |
| Jun 10, 2026 | BRADLEY WILLIAM | Director | AWARD | 22,500 | — | — |
| Jun 10, 2026 | BRADLEY WILLIAM | Director | BUY | 68,493 | $0.7348 | $50.3K |
| Jun 8, 2026 | Smith Weber Lara | Chief Financial Officer | BUY | 20,000 | $0.6854 | $13.7K |
9 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 6 neutral. Avg impact: 4.0/10.
MIXED
INST-CLUSTER
4/10
Q3 2024 13F filings show mixed institutional activity in Fractyl Health (GUTS): four funds (Woodline
Jun 12, 2026
NEUTRAL
CLUSTER
3/10
CEO Rajagopalan Harith and CFO Smith Weber Lara collectively purchased $32K worth of GUTS shares in
Jun 11, 2026
NEUTRAL
INST-CLUSTER
3/10
Three mega-passive institutional investors (Vanguard, Morgan Stanley, UBS) significantly increased t
Jun 11, 2026
BULLISH
8-K
6/10
Fractyl Health reported positive one-year open-label results from the REVEAL-1 cohort, showing that
Jun 4, 2026
NEUTRAL
PRESS-RELEASE
4/10
Fractyl Health reported Q1 2026 GAAP net income of $9.2M ($0.06/share) vs a net loss of $23.7M in Q1
May 12, 2026
NEUTRAL
8-K
4/10
Fractyl Health reported Q1 2026 results with a GAAP net income of $9.2M (EPS $0.06) vs a net loss of
May 12, 2026
BULLISH
8-K
5/10
Fractyl Health received Clinical Trial Application authorization in the Netherlands to initiate a Ph
May 11, 2026
NEUTRAL
DEFA14A
2/10
Fractyl Health, Inc. (GUTS) has filed a definitive proxy statement for its 2026 annual meeting, whic
Apr 24, 2026
NEUTRAL
8-K
5/10
Fractyl Health announced completion of participant randomization in its REMAIN-1 Pivotal Cohort stud
Feb 26, 2026
BULLISH
7/10
Fractyl Health reported positive one-year open-label data from its REVEAL-1 Cohort, showing that pat
Jun 4, 2026
BULLISH
7/10
Fractyl Health received Clinical Trial Authorization in the Netherlands to begin a Phase 1/2 first-i
May 11, 2026
NEUTRAL
4/10
Fractyl Health announced completion of randomization in the REMAIN-1 Pivotal Cohort, with topline 6-
Mar 24, 2026
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 4 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.24 mean target
+516.5% upside
Strong Buy (1.33)
$2.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $0.8500 |
| Target Low | $2.00 |
| Target Mean | $5.24 |
| Target Median | $6.20 |
| Target High | $8.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.14 | $-0.15 | $-0.14 | 75.1% | — | 3↑ 0↓ | $0.0B | 0.0% | 5 |
| Next Q 2026-09-30 |
$-0.14 | $-0.15 | $-0.14 | 79.7% | — | 4↑ 0↓ | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-0.42 | $-0.58 | $-0.35 | 77.4% | — | 4↑ 0↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-0.54 | $-0.77 | $-0.36 | -29.5% | — | 3↑ 0↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.142 | |
| 7d ago | $-0.142 | |
| 30d ago | $0.000 | -0.142 |
| 60d ago | $-0.160 | +0.018 |
| 90d ago | $-0.153 | +0.011 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 26, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
40°
Cool
Bearish
Neutral
Bullish
1 mentions
0 bullish
1 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 20, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Fractyl Health (GUTS) valuations
▲ 1
💬 1
⚡ 0.5
$GUTS is on the rise
▲ 2
💬 2
⚡ 0.0
Jun 12, 2026
short_volume
Short Volume: GUTS — 60.1% short (1.1M / 1.9M)
Short: 1,118,861 | Exempt: 12,400 | TRF Vol: 1,860,980 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
fda
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
<p align="center"><em>Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure<
May 12, 2026
earnings
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
<p align="center"><em>Next anticipated Revita</em><sup><em>®</em></sup><em> clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026
May 12, 2026
earnings_calendar
GUTS Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
fda
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
<p align="center"><em>Authorization advances Fractyl Health to a dual clinical-stage company, with Revita</em><sup><em>®</em></sup><em> in pivotal dev
May 6, 2026
short_volume
Short Volume: GUTS — 55.6% short (0.4M / 0.7M)
Short: 390,393 | Exempt: 10,499 | TRF Vol: 702,380 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: GUTS — 57.6% short (1.1M / 1.9M)
Short: 1,098,949 | Exempt: 92,581 | TRF Vol: 1,906,631 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
short_volume
Short Volume: GUTS — 58.1% short (0.4M / 0.7M)
Short: 405,558 | Exempt: 250 | TRF Vol: 697,631 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
earnings
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
<p align="center"><em>Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026</em></p>
Mar 24, 2026
earnings_calendar
GUTS Q4 2025 Earnings After Market Close — 2026-03-24
Mar 24, 2026
short_volume
Short Volume: GUTS — 62.3% short (0.5M / 0.8M)
Short: 523,158 | Exempt: 4,124 | TRF Vol: 840,271 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: GUTS — 58.3% short (1.1M / 1.8M)
Short: 1,058,276 | Exempt: 3,400 | TRF Vol: 1,815,087 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
Mar 3, 2026
earnings_calendar
GUTS Q4 2025 Earnings After Market Close — 2026-03-03